Showing 951-960 of 21419 results for "".
- AI Can Speed Design of Health Softwarehttps://reachmd.com/news/ai-can-speed-design-of-health-software/2457450/Artificial intelligence helped clinicians to accelerate the design of diabetes prevention software, a new study finds NEW YORK, March 6, 2024 /PRNewswire/ --Publishing online March 6 in the Journal of Medical In
- "20 Tips in 20 Minutes" Offers Practical Pearls at Fall Clinicalhttps://reachmd.com/news/20-tips-in-20-minutes-offers-practical-pearls-at-fall-clinical/2488740/Five dermatologists shared rapid-fire clinical, procedural, and practice-management advice, ranging from alopecia photography and nail examination to infantile hemangiomas, reimbursement, and patient communication at the 2026 Fall Clinical Dermatology Conference. The fast-moving "20 Tips i
- Bimekizumab-Treated Patients With Hidradenitis Suppurativa Remained Flare-Free Through 3 Years in Extension Studyhttps://reachmd.com/news/bimekizumab-treated-patients-with-hidradenitis-suppurativa-remained-flare-free-through-3-years-in-extension-study/2488712/Most evaluable patients with moderate-to-severe hidradenitis suppurativa (HS) receiving bimekizumab remained free of observed flares through 148 weeks, according to pooled BE HEARD I and II and BE HEARD EXT data presented at the 2026 Fall Clinical Dermatology Conference. The analysis inclu
- CRP, Lung Function Predict Outcomes After Solid-Tumor Cell Therapyhttps://reachmd.com/news/crp-lung-function-predict-outcomes-after-solid-tumor-cell-therapy/2488658/Key Takeaways Among solid-tumor cellular-therapy recipients in MD Anderson’s Houston phase I program, higher baseline CRP was associated with shorter OS, while higher infused cell dose was associated with longer PFS. In the subgroup with pulmonary function testing, h
- World Chronic Hand Eczema Day to Launch October 5https://reachmd.com/news/world-chronic-hand-eczema-day-to-launch-october-5/2488610/The first World Chronic Hand Eczema Day will take place October 5, 2026, bringing patients, clinicians, and advocacy organizations together to increase awareness of chronic hand eczema (CHE) and its effects beyond the skin, according to a press release. Hand eczema i
- Anzupgo Receives Positive CHMP Opinion for Adolescent CHEhttps://reachmd.com/news/anzupgo-receives-positive-chmp-opinion-for-adolescent-che/2488490/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication for Anzupgo (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or i
- Blood mRNA Panel May Detect Early Pancreatic Cancerhttps://reachmd.com/news/blood-mrna-panel-early-pancreatic-cancer/2488454/Key Takeaways In a single-center case-control diagnostic accuracy pilot, a 56-gene peripheral whole-blood mRNA panel detected 9 of 10 stage 0-I pancreatic ductal adenocarcinoma cases, while CA19-9 detected 1 of 10. In the sample, the combined Panregza assay was repor
- Physical and Respiratory Training in Myasthenia Gravis: Systematic Review and Meta-Analysishttps://reachmd.com/news/physical-respiratory-training-mg/2487298/Key Takeaways Across 20 myasthenia gravis studies, physical activity and respiratory muscle training were associated with improvements in several symptom and quality-of-life measures in adults with MGFA class I-III disease. MG-QOL15 favored training, w
- Full-Spectrum Cannabis Extract Trial in Chronic Low Back Painhttps://reachmd.com/news/full-spectrum-cannabis-extract-trial-in-chronic-low-back-pain/2487025/Key Takeaways In phase A, VER-01 was associated with greater pain reduction than placebo, and the prespecified neuropathic-pain endpoint also favored active treatment. Responder rates, sleep quality, physical function, quality of life, patient global i
- Single-Cycle Pembrolizumab in Localized DMMR Colon Cancerhttps://reachmd.com/news/single-cycle-pembrolizumab-in-localized-dmmr-colon-cancer/2486996/Key Takeaways Pathologic complete response was observed in 44% and major pathologic response in 57% after one pembrolizumab cycle before surgery. Pathologic complete response was higher in stage I-II disease than stage III disease, at 61% versus 33%.</